Search Results
Your search for can matches 13758 pages
Showing 7801 - 7850Clinical Practice Committee, State Affiliate Council Support Innovative Clinical Research—And So Can You
ASCO’s Clinical Practice Committee (CPC) and State Affiliate Council (SAC) have a history of supporting the Conquer Cancer Foundation of ASCO (CCF) Young Investigator Award (YIA) program. Individual members of the CPC and SAC, as well as ASCO State Affiliates, contribute funds to this philanthropic ...
Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
On August 30, 2017, tisagenlecleucel (Kymriah) was granted regular approval for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.1,2 Tisagenlecleucel is the first chimeric antigen receptor (CAR)...
Gary Kohanbash, PhD, Receives Grant From St. Baldrick’s Foundation
GARY KOHANBASH, PhD, a neuro-oncology researcher at the Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center, has been awarded a scholar grant of $298,000 from the St. Baldrick’s Foundation, a volunteer-driven charity dedicated to raising money for childhood cancer...
NCCN Guidelines to Be Integrated Into Evinance Decision Support Platform
THE NATIONAL COMPREHENSIVE Cancer Network® (NCCN®) is collaborating with Evinance to integrate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) into the Evinance Decision Support Platform to allow for point-of-care access to treatment recommendations derived from the NCCN...
U.S. Preventive Services Task Force Recommends Screening Most Adult Women for Cervical Cancer
THE U.S. PREVENTIVE SERVICES TASK FORCE has posted a draft recommendation statement and draft evidence review on screening for cervical cancer. The Task Force recommends that primary care clinicians screen for cervical cancer in women ages 21 to 29 every 3 years with cervical cytology, more...
Balancing Harms and Benefits of Cancer Screening: The Debate Continues
Over the past several decades, widespread cancer screening has saved lives from various cancer types. However, despite advances in early-detection technologies, many cancers still remain undetected until they become symptomatic, conferring poor prognoses and outcomes. Moreover, some methods of...
How Early Palliative Care May Benefit Patients With Incurable Cancer
Palliative care provided soon after a patient is diagnosed with incurable cancer not only helps improve the patient’s overall quality of life but also improves communication about the patient’s wishes for end-of-life care, according to a study by Jennifer S. Temel, MD, Clinical Director of Thoracic ...
FDA Recent Approvals Include First Oncology Biosimilar
ON SEPTEMBER 14, 2017, the U.S. Food and Drug Administration (FDA) approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the United States for the treatment of cancer....
Duration Studies in Oncology Have Often Been Poorly Designed and Analyzed
The ASCO Post is pleased to introduce “At Microphone 1,” an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings, and often at the microphone where he stands ready with important questions for...
News From JCO and JOP
STAYING UP-TO-DATE in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology (JCO) and the Journal of Oncology Practice (JOP). Future installments...
Sarcoma Management Is Slowly Evolving
THE BACKBONE treatment for soft-tissue sarcomas has long been anthracycline-based, but new approaches are coming. These novel strategies were discussed at the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, by Melinda L. Yushak, MD, MPH, Assistant Professor ...
Small Steps Forward in Brain Tumor Therapy
SOME RECENT ADVANCES in the treatment of brain tumors are promising, but others are less so, according to Jeffrey J. Olson, MD, Professor of Neurosurgery at Emory University, Atlanta. At the 2017 Debates and Didactics in Hematology and Oncology Conference, held in Sea Island, Georgia, and...
Is Complete Lymphadenectomy Still Standard of Care in Melanoma?
DOES COMPLETE lymph node dissection for sentinel node–positive melanoma still have a role in the management of this disease? That’s debatable. Although it does not improve overall survival over observation alone, complete lymphadenectomy may have other benefits, according to a dialogue at the...
Amyloidosis: Pearls for Simplifying the Diagnosis
AMYLOIDOSIS REMAINS a challenging and nuanced diagnosis. At the 2017 Debates and Didactics in Hematology and Oncology Conference, held in Sea Island, Georgia, Jonathan L. Kaufman, MD, discussed his approach to diagnosing amyloid light-chain amyloidosis. Dr. Kaufman is Associate Professor of...
Update on Nonimmunotherapy Advances in Endometrial, Cervical, and Ovarian Cancers
AT THE 12TH ANNUAL New Orleans Summer Cancer Meeting, Thomas Herzog, MD, Deputy Director of the University of Cincinnati Cancer Institute and Professor of the Division of Gynecologic Oncology at the University of Cincinnati College of Medicine, delivered an update on nonimmunotherapy advances in...
PD-L1 Inhibitor Consolidation Therapy for NSCLC: New Standard of Care?
THE PROGRAMMED CELL DEATH ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) improved progression-free survival by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) whose disease did not progress following standard treatment ...
New Response Evaluation Criteria for Lymphoma Clinical Trials: RECIL 2017
New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the RECIST criteria used for solid tumors.1 The new criteria were reported by Anas Younes, MD, of Memorial Sloan Kettering...
Hepatocellular Carcinoma: Current Thoughts on Liver Transplantation
LIVER TRANSPLANT offers the highest rates of long-term survival for patients with hepatocellular carcinoma, according to Maria Russell, MD, Assistant Professor of Surgery at Emory University, Atlanta. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia,...
Religiously Tailored Educational Intervention to Encourage Mammography in American Muslim Women
Despite the U.S. Preventive Services Task Force recommendation that women between the ages of 50 and 74 undergo mammography every 2 years, only about 50% of American Muslim women do so, compared with 67% of all American women. A study by Padela et al investigating the mammography-related barrier...
Expert Point of View: Reinhard Dummer, MD, and Jeffrey Weber, MD, PhD
ASSUMING THE regimens evaluated in COMBI-AD and CheckMate 238 are both approved by the U.S. Food and Drug Administration for the treatment of high-risk resected melanoma, clinicians may be faced with a tough choice. ESMO experts and the study’s investigators weighed in on this issue in a lively...
Adoptive Cell Therapy—Act 1: The Beginning
ON AUGUST 30, 2017, the first genetically engineered T-cell therapy (tisagenlecleucel [Kymriah]) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or...
AACR Releases 2017 Cancer Progress Report: Harnessing Research Discoveries to Save Lives
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives...
Assessing and Managing CAR T-Cell Treatment Toxicities
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists—one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for...
New ASCO Guideline Aims to Improve Clinician Communication With Patients
A new guideline from ASCO published by Gilligan et al in the Journal of Clinical Oncology outlines best practices for cancer clinicians when communicating with patients and their loved ones. The Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline...
Peter W.T. Pisters, MD, MHCM, Named Sole Finalist in Search for President, MD Anderson
The University of Texas System Board of Regents has selected Peter W.T. Pisters, MD, MHCM, as sole finalist for the position of president at The University of Texas MD Anderson Cancer Center in Houston. The regents voted unanimously to select Dr. Pisters at a special board meeting on Friday,...
ESMO 2017: 'Triggers': A New Tool to Assess Patients’ Palliative Needs
A new tool to identify patients who would benefit from early palliative care was presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA54_PR). The so-called “Triggers” tool, developed by the London Cancer Alliance to help clinicians in the...
ESMO 2017: Abdominal to Peripheral Fat Ratio May Predict Risk of Cancer Diagnosis in Postmenopausal Women
Body fat distribution in the trunk is more influential than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1408P_PR). The findings put a new spin on weight...
ESMO 2017: MONARCH 3: Abemaciclib as Initial Therapy Improves Outcome in Endocrine-Sensitive Advanced Breast Cancer
The results of the MONARCH 3 trial, presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 236O_PR), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine...
ESMO 2017: NOR-CAYACS Trial: Factors That May Limit Work Ability of Young Adult Cancer Survivors
Factors that may limit the ability of young adult cancer survivors to work were reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1110PD_PR). Late side effects can occur months or years after cancer treatment. In patients diagnosed with cancer in young...
FDA Approves First Biosimilar for the Treatment of Cancer
The U.S. Food and Drug Administration today approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to...
ESMO 2017: Study Confirms Chemoradiation Is Best Treatment for Locally Advanced Cervical Cancer
A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings were reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 928O_PR). ...
ESMO 2017: Patients May Feel Psychosocial Impact of Chemotherapy More Acutely Than Physical Side Effects
The preliminary results of a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show that sociopsychological factors have become more significant for patients today than physical side effects such as nausea and vomiting, which were among the top concerns in...
ESMO 2017: Pembrolizumab Shows Promising Response Rate in Pretreated Metastatic Gastric Cancer
Pembrolizumab (Keytruda) has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract LBA28_PR). The expected...
ESMO 2017: New Data Confirms Superiority of Docetaxel-Based Triplet Therapy in Esophagogastric Cancer
The superiority of docetaxel-based triplet therapy over standard of care in patients with resectable esophagogastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA27_PR)....
ESMO 2017: DNA Sequencing Could Open Up New Drug Indications for Patients With Rare Cancers
Due to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers but who carry the same genetic mutations. The first results of a multidrug and multitumor clinical trial (Abstract...
ESMO 2017: Combination Targeted Adjuvant Therapy Doubles Relapse-Free Survival in Stage III Melanoma
Combination targeted adjuvant therapy with dabrafenib (Tafinlar) and trametinib (Mekinist) doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented on September 11 at the European Society for Medical Oncology ...
ESMO 2017: Some Stroke Survivors May Have Underlying Cancer
Some stroke survivors may have underlying cancer, according to an observational study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1412P_PR). “Postmortem studies have suggested that cancer can develop after a stroke, but the magnitude of...
ESMO 2017: Rucaparib Boosts Progression-Free Survival in BRCA-Mutant Recurrent Ovarian Cancer
Rucaparib (Rubraca) maintenance therapy increases progression-free survival in BRCA-mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA40_PR). Most...
ESMO 2017: ICON8 Trial Reaffirms Standard Chemotherapy Dosing in Ovarian Cancer
Caucasian women with ovarian cancer can safely stick to the standard every-3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in...
ESMO 2017: ALEX and ALUR Trials: Alectinib Shows CNS Benefit in ALK-Positive NSCLC
Data from two separate phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show the particular central nervous system (CNS) activity of alectinib (Alecensa) in patients with advanced non–small cell lung cancer involving a mutation of the...
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
In a single-center experience reported in JAMA Surgery, Eng et al found that an increased intraoperative fluid rate was associated with increased perioperative morbidity in patients with peritoneal cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Study...
ESMO 2017: MINDACT Study in Early-Stage Breast Cancer Shows Even Small Tumors Can Be Aggressive
Even small tumors in the breast can be aggressive, according to a study in patients with early-stage breast cancer presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract 150O_PR). Researchers found that 24% of small tumors were aggressive, and patients...
ESMO 2017: Overuse of Tumor Marker Tests in Primary and Secondary Care
The vast majority of tumor marker tests in primary and secondary care are not necessary, according to a study presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract 1410P_PR). The tests assisted with a cancer diagnosis in just 2% of patients....
Immunologic Biomarkers and Survival in Third-Generation CAR T-Cell Therapy
A phase I/IIa study investigating the safety and effectiveness of a third-generation CD19-specific chimeric antigen receptor (CAR) T-cell therapy in patients with lymphoma or leukemia has found that the treatment led to a complete response in 6 of the 15 patients in the study and that overall...
Conquer Cancer Foundation and ASCO International Development and Education Award
Applications Being Accepted Through October 31, 2017 THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) provides support for early-career oncologists in low-and middle-income countries and facilitates the sharing of knowledge between these oncologists and ASCO members. The program pairs IDEA ...
Relationship Between Molecular Subtypes of Gastric Cancer and Prognosis
In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability, genomically stable, and chromosomal instability. However, their clinical significance is unknown. Now, a study by Bo Hwa Sohn, PhD,...
Douglas R. Lowy, MD, and John T. Schiller, PhD, to Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) will receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize,...
Zika Virus Shows Oncolytic Activity Against Glioblastoma Stem Cells in Preclinical Trial
Although Zika virus causes devastating damage to the brains of developing fetuses, it someday may prove to be an effective treatment for glioblastoma. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine showed that...
CMS Grants Disaster Exceptions/Exemptions for Medicare-Certified Providers Affected by Hurricane Harvey
The Centers for Medicare & Medicaid Services (CMS) is granting exceptions under certain Medicare quality reporting and value-based purchasing programs without having to submit an extraordinary circumstances exception request if they are located in one of the Texas counties or...
Expect Questions About Glioblastoma Symptoms
WITH THE MANY NEWS REPORTS about Senator John McCain being diagnosed with glioblastoma, patients may be asking if symptoms such as headaches and vision or speech problems should signal the need for screening or diagnostic tests. “There has never been any suggestion that doing routine screening,...
